Hydroxyurea blunts mitochondrial energy metabolism and osteoblast and osteoclast differentiation exacerbating trabecular bone loss in sickle cell mice
Abstract Sickle cell disease (SCD) is a severe hematological disorder characterized by erythrocyte sickling that causes significant morbidity and mortality. Skeletal complications of SCD include a high incidence of bone loss, especially in vertebrae, leading to fragility fractures that contribute to...
Saved in:
| Main Authors: | Ashish Kumar Tripathi, Sadaf Dabeer, Jun Song, Tatyana Vikulina, Susanne Roser-Page, Jessica A. Alvarez, David. R. Archer, M. Neale Weitzmann |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-12-01
|
| Series: | Cell Death and Disease |
| Online Access: | https://doi.org/10.1038/s41419-024-07296-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hydroxyurea Treatment for Sickle Cell Disease
by: Martin H. Steinberg
Published: (2002-01-01) -
The modern use of hydroxyurea for children with sickle cell anemia
by: Charles T. Quinn, et al.
Published: (2025-01-01) -
Is Hydroxyurea Treatment Changing the Life of Children with Sickle Cell Disease?
by: Mohammed Ali Al Sabbah, et al.
Published: (2023-07-01) -
Influence of hydroxyurea on tubular phosphate handling in sickle cell nephropathy
by: Gabriela Araujo de Abreu, et al.
Published: (2024-11-01) -
Icariin-Enhanced Osteoclast-Derived Exosomes Promote Repair of Infected Bone Defects by Regulating Osteoclast and Osteoblast Communication
by: Zhang Y, et al.
Published: (2024-11-01)